DiaSorin : launches the two fastest molecular diagnostic tests in the world to detect fulminant leukemias

DiaSorin S.p.A. specializes in the development, manufacturing and marketing of in vitro diagnostic reagents. The products are used in treating infectious and viral diseases, thyroid pathologies, cancer, etc. At the end of 2022, the group had 10 production sites located in Italy, the United States (6), Canada, Germany, and the United Kingdom.